公开(公告)号：US06210683B1

公开(公告)日：2001-04-03

申请号：US09140428

申请日：1998-08-26

Applicant: Carl Burke ,  David Volkin

Inventor： Carl Burke ,  David Volkin

IPC: A61K3925

CPC classification number: A61K47/42 ,  A61K39/0015 ,  A61K39/12 ,  A61K39/165 ,  A61K39/20 ,  A61K39/25 ,  A61K47/02 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/70 ,  C12N2710/16734 ,  Y02A50/466

Abstract: Compositions are provided for improving the stability of live virus vaccines containing, e.g., live varicella zoster, measles, mumps, and rubella viruses. Such improved stabilizers are aqueous solutions containing recombinant human serum albumin (rHA) as a component at from 1-100 g/l. Live virus vaccines as well as methods of preparing live virus vaccines containing the stabilizers are also provided.

Abstract translation: 提供了用于提高含有例如活水痘带状疱疹，麻疹，腮腺炎和风疹病毒的活病毒疫苗的稳定性的组合物。 这种改进的稳定剂是含有1-100g / l组分的重组人血清白蛋白（rHA）的水溶液。 还提供了活病毒疫苗以及制备含有稳定剂的活病毒疫苗的方法。

公开(公告)号：US20060217341A1

公开(公告)日：2006-09-28

申请号：US11431676

申请日：2006-05-10

Applicant: David Volkin ,  Robert Evans ,  Mark Bruner

Inventor： David Volkin ,  Robert Evans ,  Mark Bruner

IPC: A61K48/00 ,  C12Q1/70 ,  C12Q1/68 ,  C12N1/08

CPC classification number: A61K9/0019 ,  A61K39/12 ,  A61K39/145 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/20 ,  A61K48/00 ,  A61K2039/53 ,  C12N15/1003 ,  C12N2760/16111 ,  C12N2760/16134

Abstract: This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.

公开(公告)号：US20090181027A1

公开(公告)日：2009-07-16

申请号：US12238804

申请日：2008-09-26

Applicant: Paul Dal Monte ,  Jill Giles-Komar ,  George Heavner ,  David Knight ,  Mehrnaz Khossravi ,  Jinquan Luo ,  David Shealy ,  David Volkin

Inventor： Paul Dal Monte ,  Jill Giles-Komar ,  George Heavner ,  David Knight ,  Mehrnaz Khossravi ,  Jinquan Luo ,  David Shealy ,  David Volkin

IPC: A61K39/395 ,  A61P43/00

CPC classification number: A61K47/26 ,  A61K47/183 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/34 ,  C07K2317/76

Abstract: An anti-IL-12/23p40 antibody that binds to a portion of the IL-12 or IL-23 protein corresponding to the p40 subunit of IL-12 or IL-23, including compositions, formulations, and methods of administration have applications in diagnostic and/or therapeutic uses and devices.

Abstract translation: 结合与IL-12或IL-23的p40亚基相对应的IL-12或IL-23蛋白的一部分的抗IL-12 / 23p40抗体，包括组合物，制剂和施用方法，可应用于 诊断和/或治疗用途和装置。

公开(公告)号：US20050186225A1

公开(公告)日：2005-08-25

申请号：US11071095

申请日：2005-03-03

Applicant: Robert Evans ,  David Volkin ,  Lynne Isopi

Inventor： Robert Evans ,  David Volkin ,  Lynne Isopi

IPC: A61K9/00 ,  A61K47/00 ,  A61K48/00 ,  A61K39/235

CPC classification number: A61K9/0019 ,  A61K48/00 ,  A61K2039/525 ,  C12N2710/10343 ,  C12N2710/10351

Abstract: The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while also being compatible with parenteral administration. These formulations comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as a free radical scavenger and/or a chelating agent to inhibit free radical oxidation.

Abstract translation: 本发明涉及用于基因治疗和/或疫苗应用的病毒制剂和相关药物产品。 本文公开的特别优选的病毒制剂是液体腺病毒制剂，其在约2-8℃范围内储存时显示出改善的稳定性，同时也与肠胃外给药相容。 这些制剂包含缓冲剂，糖，盐，二价阳离子，非离子洗涤剂，以及抑制自由基氧化的自由基清除剂和/或螯合剂。